• metastatic-recurrent HNSCC (mHNSCC)
• mHNSCC - (neo)adjuvant (NA)
• mHNSCC - 1st line (L1)
• mHNSCC - L1 - all population 2
• mHNSCC - L1 - PDL1 positive 4
• mHNSCC - 2nd line (L2)
• mHNSCC - L2 - all population 4
• mHNSCC - L2 - PDL1 negative 2
• mHNSCC - L2 - PDL1 positive 1
• hepatocell cancer (HCC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus 5FU plus platin
• Immune checkpoint association
• durvalumab plus tremelimumab

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs cisplatin
• vs Standard of Care (SoC)
• vs HER inhibitor
• vs EGFR inhibitor
• vs cetuximab based chemotherapy
• vs cetuximab plus platin plus 5FU
• vs immune chekpoint inhibitors
• vs anti-CTLA-4
• vs tremelimumab
• vs anti-PD-(L)1
• vs durvalumab based treatment
• vs durvalumab alone
• vs non active control
• vs no additional treatment

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs cetuximab plus platin plus 5FU;   vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;